$IBRX 8-K SEC Filings

Filed On	Filing
14 Oct 2026	8-K: Regulation FD Disclosure FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle- Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
04 Aug 2026	8-K: Results of Operations and Financial Condition
30 Jul 2026	8-K: Regulation FD Disclosure
10 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
18 May 2026	8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
07 May 2026	8-K: Results of Operations and Financial Condition
09 Apr 2026	8-K: Results of Operations and Financial Condition
06 Apr 2026	8-K: Regulation FD Disclosure
31 Mar 2026	8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
23 Feb 2026	8-K: Results of Operations and Financial Condition
18 Feb 2026	8-K: Other Events
26 Jan 2026	8-K: Entry into a Material Definitive Agreement
15 Jan 2026	8-K: Results of Operations and Financial Condition
14 Jan 2026	8-K: Other Events
29 Dec 2025	8-K: Entry into a Material Definitive Agreement; Other Events
15 Dec 2025	8-K: Departure/Election of Directors or Officers; Compensation
12 Dec 2025	8-K: Other Events
05 Nov 2025	8-K: Results of Operations and Financial Condition
08 Aug 2025	8-K: Other Events
05 Aug 2025	8-K: Results of Operations and Financial Condition

Comments